Strides Pharma Science is well on track to achieve the FY25 outlook of $275 million-$290 million, post-demerger.
Strides Pharma Q3 Results: Profitability returns after a loss last year; Stock surges 5%
Share it
Open an Account in less than 1 Min.
Need help? Call us
+91 976 976 8500
Services
Company
Get in touch
- +91 976 976 8500
- info@markettrade.live
- Pjazza Mifsud Bonnici, Marsascala, Malta
- 333, Pali Pathar, Khar West, Mumbai, Maharashtra 400052
Copyright © 2025 Market Trade